Title :

Onsets of progression and second treatment determine survival of patients with symptomatic waldenstr�m macroglobulinemia

Author(s) :

Guidez, Stephanie [Auteur]
Centre Hospitalier de Lens
Labreuche, Julien [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Drumez, Elodie [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Ysebaert, Loic [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Bakala, Jana [Auteur]
Centre Hospitalier de Lens
Delette, Caroline [Auteur]
CHU Amiens-Picardie
Hivert, Benedicte [Auteur]
Centre Hospitalier de Lens
Protin, Caroline [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Declercq, Herve [Auteur]
Centre Hospitalier de Lens
Verlay, Melanie [Auteur]
Centre Hospitalier de Lens
Marolleau, Jean-Pierre [Auteur]
CHU Amiens-Picardie
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Morel, Pierre [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]

Journal title :

Blood Advances

Abbreviated title :

Blood Adv

Volume number :

2

Pages :

3102-3111

Publication date :

2018-11-27

ISSN :

2473-9537

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Few reports assess prognosis during follow-up of patients with symptomatic Waldenström macroglobulinemia (WM). In 121 WM patients treated between 1993 and 2016, we analyzed the prognostic role during the clinical course ...
Show more >Few reports assess prognosis during follow-up of patients with symptomatic Waldenström macroglobulinemia (WM). In 121 WM patients treated between 1993 and 2016, we analyzed the prognostic role during the clinical course of the initial International Prognostic Scoring System for WM (IPSSWM). Then, we assessed onset of response, progression, and second treatment initiation coded as time-dependent covariates. High-risk IPSSWM was an adverse prognostic factor for survival after first treatment initiation (SAFTI). Nevertheless, the corresponding Dxy concordance index obtained in multiple landmark analyses decreased from 0.24 to 0.08 during the first 6 years, in accordance with a departure from the proportional hazard assumption. By contrast with onset of response (whatever its level), onset of progression and initiation of second-line treatment retained prognostic value for SAFTI (PPShow less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T16:48:33Z
2021-05-17T06:53:35Z
2024-05-23T11:08:28Z